Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$879.48 USD

879.48
835,307

-6.07 (-0.69%)

Updated Oct 4, 2024 12:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US

by Zacks Equity Research

The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $262.32, moving +0.85% from the previous trading session.

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for USMV

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, Eli Lilly and J&J

by Zacks Equity Research

Pfizer, AbbVie, Eli Lilly and J&J are included in this analyst blog.

AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS

by Zacks Equity Research

AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.

Lilly (LLY) Inks Deal for Multiple Neurologic Indications

by Zacks Equity Research

Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug

by Kinjel Shah

FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $271.73, moving -1.63% from the previous trading session.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $276.22 in the latest trading session, marking a -0.37% move from the prior day.

Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung

by Zacks Equity Research

Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $276.43, moving -0.71% from the previous trading session.

Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use

by Zacks Equity Research

Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.

Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag

by Zacks Equity Research

Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.

Pfizer (PFE) Gets FDA's Emergency Use Nod for COVID Pill

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill Paxlovid is the first oral antiviral medicine, which can be prescribed as an at-home treatment for mild-to-moderate COVID-19.

    The Zacks Analyst Blog Highlights: Microsoft, Broadcom, Eli Lilly, Intuitive Surgical and MetLife

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Microsoft, Broadcom, Eli Lilly, Intuitive Surgical and MetLife.

    Mark Vickery headshot

    Top Research Reports for Microsoft, Broadcom & Eli Lilly

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Broadcom Inc. (AVGO), and Eli Lilly and Company (LLY).

    Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal

    by Zacks Equity Research

    Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.

    Kinjel Shah headshot

    Will Lilly and Pfizer be Top Pharma Stocks Again in 2022?

    by Kinjel Shah

    Among the large drugmakers, stocks of Pfizer (PFE) and Eli Lilly (LLY) rose significantly in 2021 in response to their pipeline progress.

    Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%

    by Zacks Equity Research

    Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022

    Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    Eli Lilly (LLY) closed the most recent trading day at $263.48, moving -1.47% from the previous trading session.

    Kinjel Shah headshot

    Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More

    by Kinjel Shah

    Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.

    Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022

    by Zacks Equity Research

    Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in 2022. It expects to complete the study in four years from the study initiation date.

    Eli Lilly (LLY) Just Reclaimed the 20-Day Moving Average

    by Zacks Equity Research

    Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

    Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average

    by Zacks Equity Research

    Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?